Biotech Values

[drbio45]

Magainin changed their name to Genaera. This biotech values board was originally the Genaera board. It was one of my biggest financial bonanzas.

They had good data in wet amd treating both eyes through an iv infusion. The data was not as good as Lucentis so there was no way it was going to get approved. The drug was given as a once weekly infusion for 4 weeks, then a person received an infusion once a month. It would not have been practical to come into the office once a week for the infusion. The problem was that the drug didn't stay in the back of the eye for more than 4 or 5 days so vision improvement only lasted for the first month.

Even with this suboptimal dosing there was stabilization of vision at the longer period of time but you didn't get the improvement seen in Lucentis.

This company bought the drug out of bankrupcy and they were able to get it made as an eyedrop because squalamine is a small molecule. The patient can now be treated on a daily basis and get the drug into the back of the eye in sufficient amounts. I guess we will see if it is a case of Zebra's Law.